AccendoWave - the only company that can remotely monitor pain. Pain is the #1 reason for a hospital readmit.

A Health Equity Solution - AccendoWave Benchmarks Pain Data with Machine Learning Technology. AccendoWave does real-time objective individual assessment of patient pain. For use with telemedicine (as you see only have the patient and loose all the non verbal pain cues), Hospital at Home, Home Care, Clinic or Urgent Care site.

AccendoWave utilizes full spectrum brain analysis and deep learning algorithms to objectively measure pain. We have the largest Global Real-Time Benchmarked Pain Database. 

Health care has a pain bias problem. Pain is one of the most subjective measures in all of medicine - and thus subject to bias. There is an extensive body of research that shows bias: women and pain, ethnicity and pain, and seniors and pain. For many in these groups - their #1 complaint is that their pain isn't believed. An unbiased medical technology which can validate patient pain is critical given Provider Health Equity pledges.

Individual patient pain can be validated and compared to a pain database for use with pain care pathways. 

AccendoWave, a Pain Data Company with machine learning pain measurement & management technology. 

AccendoWave, a Top 4 Global Best in Class Health Equity Solution and Top 15 Global Best in Class Remote Monitoring Company, benchmarks pain data (specialty, gender, age) with machine learning technology to eliminate bias, improve outcomes and reduce health care costs. Incubated by HCA (188 Hospitals & 5-6% US Inpatient Care) - Samsung and AT&T are our partners.

AccendoWave has nine objective benchmarked pain databases (Women, Oncology, Maternal Health, Emergency Room, MSK, Med/Surg, ICU, Seniors, Adults). 

Pain is the primary reason patients access healthcare - so pain is a primary driver of health care cost. Pain levels don't show up in claims data nor can objective pain levels be extracted from EHR's. So Employers/Health Plans/Hospitals/Government have no visibility into or data on the primary driver of health care costs.  

Pain has a bias problem. There is extensive research & RWD showing bias: women and pain, ethnicity and pain, seniors and pain. 

The real world data from our health care systems is crushinly similar. #1 complaint of patients of color is that their pain isn't believed. This results in less pain medicine given to these patients and later stage cancer diagnosis.  

Given the new state, health plan and CMS initiatives on health equity, and the recent massive (150 - 250M) hospital pain lawsuits, health systems must utilize objectve pain data and focus on this pain bias problem. 

Additionally, a patient whose pain isn't believed doesn't trust their provider or health care system, and their patient experience is a zero. 

AccendoWave provides objective benchmarked pain data and insights to eliminate pain bias, improve care and reduce stakeholder healthcare costs. 

AccendoWave utilizes full spectrum brain analysis and deep learning algorithms to measure & monitor discomfort/pain. AccendoWave has four products: 

1. Digital Opioid Alternative (Hospital & Home) Value Proposition - Reduce Opioid Usage, Reduce Length of Stay, and Improve Patient Satisfaction. Most Cost Effective Choice to Meet The Joint Commission Non Pharma Pain Treatment Modality Requirement. Home - to reduce opioid usage in the transition from hospital to home. *AT&T reimburses for AccendoWave for 30 days post hospital discharge. 

2. UV Sanitizing & Charging Technology (Hospital) Value Proposition - Infection Control and Simplified Charging for AccendoWave Hospital Technology. 

3. Top 15 Global Best in Class Remote Pain Monitoring Technology. Value Proposition - Objective Data Insights into Pain - A Primary Driver of Cost & Outcomes. *AT&T reimburses for AccendoWave for 30 days post hospital discharge. 

4. Largest Global Real-Time Database on Pain with Nine Separate Objective Pain Databases. Value Proposition - Objective Pain Benchmarked Data to Address Health Equity, Improve Operational Performance, Reduce Pain Lawsuit Risk, Reduce Costs, Improve Patient Satisfaction, and Demonstrate Outcomes. 

VPExam provides optimal longitudinal Heart Failure management with continuity of care from home the clinic to the ER to the ICU and back.

The mission is to decentralize access to Cardiovascular Care. Our platform facilitates a highly effective and efficient transitional care program for cardiac patients, initially focusing on heart failure. The VPExam platform assists in the early detection of cardiac abnormalities and decompensation by proactively managing patient care: the physician improves patient quality of care, reducing re-hospitalizations and delivering more efficient, cost-effective care to the patient. The VPExam platform overcomes the barriers of traditional telemedicine, allowing comprehensive physical examinations utilizing Augmented Reality (AR) guidance.

AccendoWave is the only company that can remotely objectively measure individual patient pain. The technology can be used in the hospital and to remotely monitor and manage patient pain at home or in non acute care settings.

AccendoWave has the largest global database on pain and offers the only remote pain monitoring solution.

• We partner with Cardiologists to improve the lives of their patients by overcoming barriers of traditional telemedicine using optimized VPExam virtual care workflows.

• VPExam is the first cardiology focused value-based care company to use technology and continuous care management to deliver peer reviewed publications documenting improved health with reduced readmissions and mortality of cardiovascular patients while significantly reducing cost of care.

o Enables better care for sicker and more complex HF patients.

o Cost effective and portable care to reach high-risk underserved populations in nursing facilities, hospitals, offices, and into the home.

o Customized to each physician with actionable and timely results.

• VPExam Virtual Care for Heart Failure Optimizing Transitions (VPExam QI)

o Revealed 84% moderate clinical modification in care, 40.1% reduction in 30-day rehospitalization, 56.3% reduction in 30-day mortality, 100% compliance with

follow up, and 0% technical errors.

• Growing industry recognition for multiple publications and awards including the Heart Rhythm Society (HRS) Breakthrough Innovation in Cardiovascular Digital Health and Digital Health Hub Foundation 2023 Best in Class Next Generation Telemedicine awards.